Trial Profile
A Study to Evaluate Whether the Pre-existence of Resistance Variants Against Telaprevir Affect the Response to Telprevir plus Peginterferon alfa 2b and Ribavirin Combination Therapy in Patients with Hepatitis C Virus (HCV) Genotype 1b Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 18 Dec 2015 New trial record